Anaphylaktische Reaktionen nach COVID-19-Impfung in Deutschland

Anaphylactic reactions after COVID-19 vaccination in Germany For the COVID-19 vaccines used in Germany, severe allergic (anaphylactic) reactions after vaccination have been reported in very rare cases. While Comirnaty & REG; ( BioNTech Manufacturing GmbH) and Spikevax & REG; (MODERNA BIOTECH SPAIN, S.L.) are mRNA vaccines, Vaxzevria & REG; (AstraZeneca AB) and Jcovden & REG; (Janssen- Cilag International NV) comprise vector vaccines, and Nuvaxovid & REG; (Novavax CZ a.s.) a recombinant spike protein vaccine. The reporting rate of anaphylaxis after mRNA vaccination was higher in females receiving their first vaccination dose, with 0.97 and 1.12 reports per 100,000 vaccinations for Comirnaty & REG; ( BioNTech Manufacturing GmbH) and Spikevax & REG; (Moderna Biotech Spain, S.L.), respectively, compared with vaccinated males and subsequent vaccinations. The Paul-Ehrlich-Institut (PEI) investigated 106 responses of 321 cases of confirmed anaphylactic reactions concerning subsequent allergy testing and revaccination with a COVID-19 vaccine. The collected data indicate that only a small proportion of cases (22%) were IgE-mediated reactions. A large proportion (73%) of patients could be revaccinated under precautionary measures without recurrence of anaphylaxis. The pathomechanism of the majority of anaphylactic reactions remains unclear and should be investigated in further studies.